Showing 41-60 of 646 for: Cochrane Systematic Reviews > Psychiatric and substance abuse 
- Antidepressants for people with both schizophrenia and depression
Cochrane Systematic Reviews, 12-Mar-2013
Depressive symptoms, often of substantial severity, are found in 50% of newly diagnosed suffers of schizophrenia and 33% of people with chronic schizophrenia who have relapsed. Depression is associated with dysphoria, disability, reduction of motivation t
- Antidepressants for smoking cessation
Cochrane Systematic Reviews, 22-Apr-2020
Whilst the pharmacological profiles and mechanisms of antidepressants are varied, there are common reasons why they might help people to stop smoking tobacco. Firstly, nicotine withdrawal may produce depressive symptoms and antidepressants may relieve the
- Antidepressants for the negative symptoms of schizophrenia
Cochrane Systematic Reviews, 26-Apr-2012
Negative symptoms are common in people with schizophrenia and are often difficult to treat with antipsychotic drugs. Treatment often involves the use of various add-on medications such as antidepressants.
- Antidepressants for treating depression in dementia
Cochrane Systematic Reviews, 22-Oct-2008
The use of antidepressants for patients with dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. Many of the individual trials of antidepressants have been too small to provide precise estimates of the mode
- Antidepressants plus benzodiazepines for major depression
Cochrane Systematic Reviews, 31-Oct-2008
Anxiety frequently coexists with depression. Adding benzodiazepines to antidepressants is commonly used to treat people with depression, although there has been no convincing evidence to show that such a combination is more effective than antidepressants
- Antidepressants versus placebo for depression in primary care
Cochrane Systematic Reviews, 11-Apr-2014
Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness of antidepressant medication. There is a need to review the evidence of only those studies that have been conducted comp
- Antidepressants versus placebo for people with bulimia nervosa
Cochrane Systematic Reviews, 31-Oct-2008
Bulimia Nervosa (BN) represents an important public health problem and is related to serious morbidity and even mortality. This review attempted to systematically evaluate the use of antidepressant medications compared with placebo for the treatment of bu
- Antidepressants versus placebo for the depressed elderly
Cochrane Systematic Reviews, 31-Oct-2008
Depression warranting intervention is found in ten percent of people over the age of 60. Older depressed people are more likely to die than non-depressed. Relatively few receive therapeutic interventions, and those that do, tend to receive low dose antide
- Antidepressants versus psychological treatments and their combination for bulimia nervosa
Cochrane Systematic Reviews, 24-Feb-2010
Psychotherapeutic approaches, mainly cognitive behavior therapy, and antidepressant medication are the two treatment modalities that have received most support in controlled outcome studies of bulimia nervosa.
- Antiglucocorticoid treatments for mood disorders
Cochrane Systematic Reviews, 4-Dec-2015
Antiglucocorticoids may have antidepressant effects and have been reported to be efficacious in the treatment of severe psychiatric disorders. The efficacy and safety of antiglucocorticoid treatments for mood disorders is the subject of this systematic re
- Antipsychotic drug treatment for elderly people with late-onset schizophrenia
Cochrane Systematic Reviews, 10-Jan-2013
Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schi
- Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum
Cochrane Systematic Reviews, 20-Oct-2008
Antipsychotics are commonly prescribed for women suffering psychotic illnesses during pregnancy and the postpartum period. The potential adverse consequences of these different options are multiple and complex, impacting on the foetus, neonate, infant and
- Antipsychotic medication for challenging behaviour in people with learning disability
Cochrane Systematic Reviews, 11-Nov-2008
The term 'challenging behaviour', in the absence of psychiatric disorder, encompasses a wide range of behaviours that may be harmful to people or property, may be difficult to manage and may limit access to community facilities. Antipsychotic medications
- Antipsychotic medication for childhood-onset schizophrenia
Cochrane Systematic Reviews, 26-Apr-2012
Childhood-onset schizophrenia is schizophrenia with onset prior to the age of 13 years. Although it is rare, people who suffer from schizophrenia at an early age appear to have a clinically severe form of the illness with poor long-term prognosis. Antipsy
- Antipsychotic medication for early episode schizophrenia
Cochrane Systematic Reviews, 4-Oct-2011
Long-term treatment with antipsychotic medications in early episode schizophrenia spectrum disorders is common, but both short and long-term effects on the illness are unclear. There have been numerous suggestions that people with early episodes of schizo
- Antipsychotic medication for elderly people with schizophrenia
Cochrane Systematic Reviews, 10-Nov-2009
A large and growing number of older people across the world suffer from schizophrenia. Recommendations for their treatment are largely based on data extrapolated from studies of the use of antipsychotic medications in younger populations. In addition most
- Antipsychotic medication versus placebo for people with both schizophrenia and learning disability
Cochrane Systematic Reviews, 17-Dec-2012
Antipsychotic medication is the standard treatment for people with learning disability and schizophrenia.
- Antipsychotic medications for cocaine dependence
Cochrane Systematic Reviews, 17-Mar-2016
Cocaine dependence is a public health problem characterised by recidivism and a host of medical and psychosocial complications. Cocaine dependence remains a disorder for which no pharmacological treatment of proven efficacy exists.
- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
Cochrane Systematic Reviews, 24-Jan-2013
Weight gain is common for people with schizophrenia and this has serious implications for a patient's health and well being. Switching strategies have been recommended as a management option.
- Antipsychotics for delirium
Cochrane Systematic Reviews, 22-Oct-2008
Delirium occurs in up to 30% of hospitalised patients and is associated with prolonged hospital stay and increased morbidity and mortality. Recently published reports have suggested that the standard drug for delirium, haloperidol, a typical antipsychotic
